{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:08:12Z","timestamp":1792195692983,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ahj.2018.08.004","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T10:05:28Z","timestamp":1534500328000},"page":"110-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention"],"prefix":"10.1016","volume":"205","author":[{"given":"Laura","family":"Mauri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay J.","family":"Kirtane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold L.","family":"Dauerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Christen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic J.","family":"Allocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian T.","family":"Meredith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean J.","family":"Kereiakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.ahj.2018.08.004_bb0005","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ahj.2018.08.004_bb0010","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jcin.2015.10.001","article-title":"Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents","volume":"9","author":"Hermiller","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"10.1016\/j.ahj.2018.08.004_bb0015","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2018.08.004_bb0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"10073","key":"10.1016\/j.ahj.2018.08.004_bb0025","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2018.08.004_bb0030","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.ahj.2018.08.004_bb0035","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.ahj.2018.08.004_bb0040","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The optimize randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ahj.2018.08.004_bb0045","first-page":"722","article-title":"Safety of an abbreviated duration of dual antiplatelet therapy (\u22646 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials","volume":"87","author":"Ziada","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2018.08.004_bb0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijcard.2014.12.037","article-title":"Safety of short-term dual antiplatelet therapy after drug-eluting stents: An updated meta-analysis with direct and adjusted indirect comparison of randomized control trials","volume":"181","author":"Bulluck","year":"2015","journal-title":"Int J Cardiol"},{"issue":"18","key":"10.1016\/j.ahj.2018.08.004_bb0055","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jacc.2017.09.011","article-title":"Lesion complexity and outcomes of extended dual antiplatelet therapy after percutaneous coronary intervention","volume":"70","author":"Yeh","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.ahj.2018.08.004_bb0060","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond one year after percutaneous coronary intervention: an analysis from the randomized dual antiplatelet therapy study","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"issue":"9906","key":"10.1016\/j.ahj.2018.08.004_bb0065","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ahj.2018.08.004_bb0070","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/eurheartj\/ehr479","article-title":"Lower risk of stent thrombosis and restenosis with unrestricted use of \u201cnew-generation\u201d drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)","volume":"33","author":"Sarno","year":"2012","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ahj.2018.08.004_bb0075","first-page":"E247","article-title":"The SYNERGY biodegradable polymer everolimus eluting coronary stent: Porcine vascular compatibility and polymer safety study","volume":"86","author":"Wilson","year":"2015","journal-title":"Catheter Cardiovasc Interv"},{"issue":"17","key":"10.1016\/j.ahj.2018.08.004_bb0080","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.4244\/EIJ-D-17-00529","article-title":"Final five-year clinical outcomes in the EVOLVE trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent","volume":"13","author":"Meredith","year":"2018","journal-title":"EuroIntervention"},{"issue":"4","key":"10.1016\/j.ahj.2018.08.004_bb0085","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.002372","article-title":"Efficacy and safety of a novel bioabsorbable polymer-coated everolimus-eluting coronary stent: The EVOLVE II randomized trial","volume":"8","author":"Kereiakes","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2018.08.004_bb0090","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","author":"The GUSTO Investigators","year":"1993","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ahj.2018.08.004_bb0095","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.ahj.2018.08.004_bb0100","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ahj.2018.08.004_bb0105","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ahj.2018.08.004_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","volume":"11","author":"Rao","year":"1988","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2018.08.004_bb0115","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.amjcard.2015.11.043","article-title":"One-year outcomes in \u201creal-world\u201d patients treated with a thin-strut, platinum-chromium, everolimus-eluting stent (from the PROMUS Element Plus US Post-Approval Study [PE-Plus PAS])","volume":"117","author":"Kandzari","year":"2016","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.ahj.2018.08.004_bb0120","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.4244\/EIJY15M01_07","article-title":"One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent: the multicentre PROMUS Element European Post-Approval Surveillance Study","volume":"10","author":"Thomas","year":"2015","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2018.08.004_bb0125","author":"U.S. Department of Health and Human Services"},{"issue":"9872","key":"10.1016\/j.ahj.2018.08.004_bb0130","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ahj.2018.08.004_bb0135","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"issue":"10115","key":"10.1016\/j.ahj.2018.08.004_bb0140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ahj.2018.08.004_bb0145","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ahj.2018.08.004_bb0150","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ahj.2018.08.004_bb0155","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ahj.2018.08.004_bb0160","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jcin.2015.05.026","article-title":"Stent thrombosis in drug-eluting or bare-metal stents in patients receiving dual antiplatelet therapy","volume":"8","author":"Kereiakes","year":"2015","journal-title":"JACC Cardiovasc Interv"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318302461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318302461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:01:06Z","timestamp":1757570466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870318302461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":32,"alternative-id":["S0002870318302461"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2018.08.004","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2018.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}